India, July 22 -- BridgeBio Pharma Inc. (BBIO), a commercial-stage biopharmaceutical company, on Wednesday announced acceptance of the new drug application (NDA) for encaleret in treating autosomal dominant hypocalcemia type 1 by the U.S. Food and Drug Administration (FDA).
Autosomal dominant hypocalcemia type 1 (ADH1) is a form of hyperparathyroidism, that arises due to variations in the CASR gene that controls the calcium sensing receptor. This receptor controls blood calcium levels by regulating parathyroid hormone secretion and calcium reabsorption in the kidneys.
Symptoms of hypocalcemia may include severe muscle cramps, muscle spasms (tetany), a burning or prickling sensation in the hands or feet (paresthesia), brain fog, fatigue, a...